Pharmaceutical News and Articles

AHA: High Cardiovascular Health Linked to Lower Phenotypic Age

There is an inverse association for cardiovascular health (CVH) with phenotypic age (PhenoAge) and phenotypic age acceleration (PhenoAgeAccel), according to a s

Vitamin D Insufficiency Linked to Paclitaxel-Induced Neuropathy

Pretreatment vitamin D insufficiency is associated with an increased incidence of grade 3 chemotherapy-induced peripheral neuropathy (CIPN) from paclitaxel, acc

Playkit May Aid Children in Preparing for MRI

A mixed reality playkit may help children prepare for magnetic resonance imaging (MRI) and reduce the need for anesthesia, according to a study published online

Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention

Tirzepatide provides substantial additional reduction in body weight in participants who already achieved 5.0 percent weight reduction with an intensive lifesty

FDA Approves Zepbound (tirzepatide) for Chronic Weight Management

FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro

A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday.Th

New Postpartum Depression Drug Comes With Hefty Price Tag

A new drug to treat postpartum depression will cost nearly 16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won

AHA: Depression, Anxiety Linked to CVD Risk Factors, MACE

Depression and anxiety are associated with an increased risk for cardiovascular disease risk factors (CVDRFs) and major adverse cardiovascular events (MACE), an

ASN: Multicomponent Intervention Does Not Increase Steps Toward Kidney Transplant

A multicomponent intervention does not increase the rate of completed steps toward receiving a kidney transplant, according to a study published online Nov. 3 i

ASN: eGFR No Different With Sparsentan, Irbesartan in Focal Segmental Glomerulosclerosis

No significant differences are seen in the estimated glomerular filtration rate (eGFR) with sparsentan versus irbesartan among patients with focal segmental glo